Role of the pituitary gland in experimental hormonal induction and prevention of benign prostatic hyperplasia in the dog.
The antiandrogen, cyproterone acetate (CPA), prevents development of prostatic hyperplasia, induced in castrated dogs by a 6 month-treatment with 5 alpha-androstane-3 alpha, 17 beta-diol (A)alone or in combination with 17 beta-oestradiol (E2). The immunoperoxidase technique was used to study functional cell types in the pars distalis of the pituitary gland and to detect growth hormone (GH) and prolactin (PRL) target sites in the prostate gland. Homologous radioimmunoassays for estimation of serum canine GH and PRL concentrations were also performed. Treatment with the combinations A + E2 and A + E2 + CPA resulted in morphological indications of stimulated GH and PRL cells and depressed gonadotrophs. This correlates well with an increase in PRL-dependent staining in glandular epithelium and fibromuscular tissue of the prostate gland. However, basal serum PRL and GH levels were not significantly affected. Treatment with A and A + E2 stimulated, while additional treatment with CPA clearly suppressed adrenocorticotrophin/melanotrophin (ACTH/MSH) cells. These findings indicate that an endocrine imbalance in hypothalamic-pituitary-adrenal function may be involved in induction and prevention of prostatic hyperplasia in the dog.
D015113:Androstane-3,17-diol / Q000494:pharmacology; D000818:Animals; D002369:Castration; D003534:Cyproterone / Q000494:pharmacology*; D004285:Dogs; D004958:Estradiol / Q000494:pharmacology; D013006:Growth Hormone / Q000032:analysis / Q000097:blood; D008297:Male; D010903:Pituitary Gland, Anterior / Q000166:cytology / Q000503:physiopathology*; D011388:Prolactin / Q000032:analysis / Q000097:blood; D011467:Prostate / Q000032:analysis; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000503:physiopathology*
D015113:Androstane-3,17-diol; D004958:Estradiol; D011388:Prolactin; D013006:Growth Hormone; D003534:Cyproterone